These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34309108)

  • 1. Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran.
    Noroozi A; Conigrave KM; Mirrahimi B; Bastani P; Charkhgard N; Salehi M; Narenjiha H; Vaziri A; Kebriaeezadeh A
    Drug Alcohol Rev; 2022 Feb; 41(2):419-429. PubMed ID: 34309108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opium tincture-assisted treatment for opioid use disorder: A systematic review.
    Noroozi A; Kebriaeezadeh A; Mirrahimi B; Armoon B; Ahounbar E; Narenjiha H; Salehi M; Karamouzian M
    J Subst Abuse Treat; 2021 Oct; 129():108519. PubMed ID: 34119894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial.
    Nikoo M; Kianpoor K; Nikoo N; Javidanbardan S; Kazemi A; Choi F; Vogel M; Gholami A; Tavakoli S; Wong JSH; Moazen-Zadeh E; Givaki R; Jazani M; Mohammadian F; Moghaddam NM; Schütz C; Jang K; Akhondzadeh S; Krausz M
    Addiction; 2023 Feb; 118(2):284-294. PubMed ID: 35971297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran.
    Song MJ; Westenberg JN; Kianpoor K; Nikoo M; Kazemi A; Schuetz C; Jang K; Gholami A; Akhondzadeh S; Krausz M
    Drug Alcohol Rev; 2022 May; 41(4):895-901. PubMed ID: 35170124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.
    Nikoo M; Moazen-Zadeh E; Nikoo N; Javidanbardan S; Kazemi A; Choi F; Vogel M; Gholami A; Tavakoli S; Givaki R; Jazani M; Mohammadian F; Markazi Moghaddam N; Goudarzi N; Schutz C; Jang K; Akhondzadeh S; Krausz M
    Int J Methods Psychiatr Res; 2019 Mar; 28(1):e1768. PubMed ID: 30714249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tincture of opium for treating opioid dependence: a systematic review of safety and efficacy.
    Nikoo M; Nikoo N; Anbardan SJ; Amiri A; Vogel M; Choi F; Sepehry AA; Bagheri Valoojerdi AH; Jang K; Schütz C; Akhondzadeh S; Krausz M
    Addiction; 2017 Mar; 112(3):415-429. PubMed ID: 27740713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of methadone, opium tincture and buprenorphine maintenance therapies on thyroid function in patients with OUD.
    Shakeri H; Hejrati R; Hojjat SK; Khalili MN; Farazmand T; Mollazadeh S
    J Addict Dis; 2020; 38(4):514-519. PubMed ID: 32749208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
    Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
    Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 12. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.
    Husain JM; Cromartie D; Fitzelle-Jones E; Brochier A; Borba CPC; Montalvo C
    J Subst Abuse Treat; 2023 Jan; 144():108918. PubMed ID: 36403456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys.
    Carlisle VR; Maynard OM; Bagnall D; Hickman M; Shorrock J; Thomas K; Kesten J
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
    Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
    Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing the Effects of Methadone, Buprenorphine, and Opium Tincture Maintenance Therapy on Sexual Function.
    Kheradmand A; Fazeli A; Mazaheri Meybodi A
    Addict Health; 2019 Apr; 11(2):120-128. PubMed ID: 31321009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
    Nayak SM; Huhn AS; Bergeria CL; Strain EC; Dunn KE
    Drug Alcohol Depend; 2021 Apr; 221():108649. PubMed ID: 33640679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
    Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
    Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Bates AE; Martin-Misener R
    Can J Nurs Res; 2022 Mar; 54(1):15-26. PubMed ID: 33615847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
    Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
    Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.